1. Ziel: 20 statt 50! Aktuelle Daten zum Zielwert der Testosteronsenkung und die Forschung hierüber seit erster „LH-RH“ (GnRH)-Analoga-Gabe an Patienten vor 40 Jahren
   Peter Hammerer et al, 2020, Aktuelle Urologie CrossRef
2. Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer
   Mona Kafka et al, 2020, Urologic Oncology: Seminars and Original Investigations CrossRef
3. Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis
   Mélanie Claps et al, 2018, Clinical Genitourinary Cancer CrossRef
4. Serum testosterone levels and testosterone ‘bounce’ phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer
   Yu Guang Tan et al, 2021, Urologic Oncology: Seminars and Original Investigations CrossRef
5. Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
   In-Wha Kim et al, 2019, Frontiers in Oncology CrossRef
6. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis
   Yuanjie Niu et al, 2018, Cancer Letters CrossRef
7. Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
   Paula Kappler et al, 2021, Scientific Reports CrossRef
8. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer
   Masaki Shiota et al, 2019, Urologic Oncology: Seminars and Original Investigations CrossRef
9. Higher serum testosterone levels predict poor prognosis in castration‐resistant prostate cancer patients treated with docetaxel
   Keisuke Ando et al, 2020, The Prostate CrossRef
10. Deficiency of NEIL3 Enhances the Chemotherapy Resistance of Prostate Cancer
    Yiwei Wang et al, 2021, International Journal of Molecular Sciences CrossRef